Drug Susceptibility Test for M. tuberculosis in 7 days
The QDST™ provides results within 7 days whereas conventional methods requiring 28 – 42days.
Implementation of M. tuberculosis treatment efficacy and reduction of side effects of drug through a rapid and accurate diagnosis
Reduction of cost and drug resistance through avoiding drugs misuse or overuse
QDST™ is an innovative product designed to take full advantage of solid and liquid media based drug susceptibility testing and to identify susceptibility to 13 different drugs in 7days using our patented dedicated microfluidic chip.
QuantaMatrix is a global diagnostics company committed to improving patient outcomes through rapid antimicrobial susceptibility test directly from positive blood culture.
QuantaMatrix is a company dedicated to improving patient outcomes through improved operational efficiency of rapid antibiotic susceptibility testing. Reducing the AST time to result from days to hours may positively impact the clinical outcome of patients battling life-threatening microbial infections because doctors are provided a definitive answer regarding the sensitivity of the antibiotics available for treatment. There are additional patient and administration benefits that dRAST may aid in, such as supporting antibiotic stewardship, reducing the cost of treatment through reduced length of hospital stays, reduced relapses, improved mortality rates.